Palbocent 125 mg is identified on this website as a product containing palbociclib 125 mg. Product-specific manufacturer and authorization details require verification.
Palbociclib is an oral CDK4/6 inhibitor used in selected breast cancer treatment settings.
Current U.S. labeling includes specified HR-positive/HER2-negative breast cancer settings and, following a 2026 FDA approval, an HR-positive/HER2-positive maintenance setting after induction treatment.
Palbociclib is generally classified as a targeted anticancer therapy and CDK4/6 inhibitor rather than conventional cytotoxic chemotherapy.
It inhibits CDK4 and CDK6, proteins involved in regulating cell-cycle progression.
The current U.S. IBRANCE starting dose is 125 mg once daily for 21 days followed by 7 days off.
The standard labeled schedule is cyclical: 21 days of treatment followed by 7 days off.
Capsules are taken with food under current U.S. labeling. Tablets may be taken with or without food.
Neutropenia, infections, leukopenia, fatigue, nausea, stomatitis, anemia, diarrhea, alopecia and thrombocytopenia are among commonly reported effects.
Yes. Neutropenia is the most frequently reported adverse reaction and requires CBC monitoring.
Yes. Palbociclib-associated neutropenia can increase susceptibility to infections.
Serious ILD/pneumonitis can occur. New or worsening respiratory symptoms require prompt medical assessment.
Yes. Strong CYP3A inhibitors and strong CYP3A inducers are important interaction concerns.
Palbociclib can cause fetal harm and should be managed according to applicable pregnancy and contraception guidance.
Current U.S. labeling advises against breastfeeding during treatment and for 3 weeks after the final dose.
Yes. CBC monitoring is specifically recommended because of the risk of neutropenia.
Current U.S. labeling identifies 75 mg, 100 mg and 125 mg capsule and tablet strengths.
The products should not be described as identical without product-specific evidence. They may contain the same active ingredient, but manufacturer, formulation, excipients and authorization can differ.
Pfizer developed palbociclib and IBRANCE.
The manufacturer of the specific Palbocent product is [Information requires verification].
This is [Information requires verification]. Pfizer is documented as the developer and company associated with the reference product IBRANCE, but that does not establish that Pfizer manufactures Palbocent.
IBRANCE is the established reference product for palbociclib in major regulatory contexts, including the EU.
The actual packaging, manufacturer, batch information, expiry date and applicable regulatory documentation should be checked. No Palbocent-specific authentication system should be claimed without verification.